Viral Kansara
Chief Discovery & Development Advisor NeuParadigmBio
Dr. Kansara is an ophthalmology drug developer with 17+ years of experience advancing innovative science from concept to approved therapy. He is currently Chief Discovery Advisor at NeuParadigm Bio, and has held progressive leadership and executive roles at Merck, Novartis, and Clearside Biomedical. He has advanced multiple drug development programs through nonclinical and clinical milestones, including FDA approval of the first commercial suprachoroidal steroid therapy, XIPERE. Dr. Kansara is passionate about transforming molecules into medicines. He builds the scientific and operational infrastructure, cross-functional teams, and strategic partnerships. Dr. Kansara serves as a mentor for the ARVO Early Career Mentorship Program. He has published and presented his research at numerous national and international scientific conferences.
Seminars
- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success
- The Next Generation of Long-Acting Ocular Delivery: Next-generation targeted and minimally invasive delivery systems beyond Intravitreal Injections to extend ocular exposure and reduce treatment burden
- Precision and Repeatable Office-Based Therapy: Advancing non-viral vectors, ASOs, siRNA, and other platforms for precise, durable, and potentially repeatable ocular therapies
- Engineering Exposure, Not Just Dose: Integrating tissue targeting, PK/PD, biomarkers, and digital twins to optimize ocular exposure, therapeutic windows, and patient selection
- AI-Powered Drug Delivery: Leveraging AI to design delivery systems, predict tissue exposure, optimize formulations, and enable more personalized ocular therapies
